Evaluation de la Congestion en Hospitalisation de Jour Pour un Bilan d'Insuffisance Cardiaque Chronique à Fraction d'éjection altérée ou modérément altérée CHF-COV Reduced (Chronic Heart Failure With Reduced Ejection Fraction - COngestion eValuation)

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Behavioral, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation. The main objective of the CHF-COVReduced study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF with reduced left ventricular ejection fraction that are associated with the risk of all-cause death, hospitalization for acute HF or IV diuretics injection in a day hospital.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with chronic acute heart failure with reduced ventricular ejection fraction admitted in hospital for scheduled day hospitalization or in consultation

• Patient with altered (left ventricular ejection fraction \<40%) and moderately altered (left ventricular ejection fraction between 40 and 50%) left ventricular ejection fraction

• Age ≥18 years

• Patients having received complete information regarding the study design and having signed their informed consent form.

• Patient affiliated to or beneficiary of a social security scheme.

Locations
Other Locations
France
CHRU de Nancy
RECRUITING
Vandœuvre-lès-nancy
Contact Information
Primary
Nicolas GIRERD, MD, PhD
n.girerd@chru-nancy.fr
0033383157322
Time Frame
Start Date: 2021-12-14
Estimated Completion Date: 2029-06-14
Participants
Target number of participants: 200
Treatments
Experimental: Patients with chronic HF with reduced ventricular ejection fraction coming for scheduled day
Related Therapeutic Areas
Sponsors
Leads: Pr. Nicolas GIRERD

This content was sourced from clinicaltrials.gov

Similar Clinical Trials